Abstract Cellular senescence is a dynamic, multistage biological program that exerts context-dependent effects on tumor initiation, progression, and overall carcinogenesis. Our laboratory has previously demonstrated that the early accumulation of p16Ink4a-expressing (representing strong cyclin-dependent kinase inhibition) senescent alveolar macrophages during tumorigenesis actively facilitates tumor formation and progression by inhibiting the infiltration of cytotoxic T lymphocytes. However, considering the dynamic nature of cellular senescence, distinct senescent cell populations could express high amounts of the alternative cell cycle inhibitor p21Waf1/Cip1 independently of p16Ink4a to potentially catalyze distinct functions. To test this, we have employed transgenic p21-ATTAC (p21-driven apoptosis through targeted activation of caspase 8) mice to investigate the role of p21-expressing cells during Kras-driven adenoma formation. In agreement with our previous observations following clearance of p16-expressing senescent cells, we found that removal of p21+ cells attenuates early tumor development. Western blot and immunofluorescence analyses corroborates a reduction in p21, p16, and multiple members of a putative senescence-associated secretory phenotype (SASP). Although senescent alveolar macrophages remain a critical therapeutic target, here we found that senescent endothelial cells also exhibited elevated expression of p21, p16, and SASP with a high senolytic response. Future studies will include identifying the predominant p21-expressing senescent endothelial subpopulations and elucidating the mechanisms by which endothelial senescence contributes to lung tumorigenesis. Collectively, our findings have unveiled additional senescent cell populations with the potential to drive lung tumorigenesis. Citation Format: Yuanning Du, Luis I. Prieto, Karthikbabu Jeganathan, Cheng Zhang, Hu Li, Darren Baker. Elucidating the role of p21 + senescent cells in early-stage lung tumorigenesis abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2268.
Du et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: